188 related articles for article (PubMed ID: 30278192)
1. G protein-coupled receptor heteromers are key players in substance use disorder.
Derouiche L; Massotte D
Neurosci Biobehav Rev; 2019 Nov; 106():73-90. PubMed ID: 30278192
[TBL] [Abstract][Full Text] [Related]
2. Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2014 Sep; 171(18):4155-76. PubMed ID: 24916280
[TBL] [Abstract][Full Text] [Related]
3. Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.
Gomes I; Fujita W; Chandrakala MV; Devi LA
Prog Mol Biol Transl Sci; 2013; 117():207-65. PubMed ID: 23663971
[TBL] [Abstract][Full Text] [Related]
4. Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology.
Stockton SD; Devi LA
Drug Alcohol Depend; 2012 Mar; 121(3):167-72. PubMed ID: 22115888
[TBL] [Abstract][Full Text] [Related]
5. Arrestin recruitment and signaling by G protein-coupled receptor heteromers.
Mores KL; Cassell RJ; van Rijn RM
Neuropharmacology; 2019 Jul; 152():15-21. PubMed ID: 30419245
[TBL] [Abstract][Full Text] [Related]
6. Understanding the role of heteroreceptor complexes in the central nervous system.
Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S
Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022
[TBL] [Abstract][Full Text] [Related]
7. Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.
Moreno E; Quiroz C; Rea W; Cai NS; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; Ferré S
J Neurosci; 2017 Feb; 37(5):1176-1186. PubMed ID: 28007761
[TBL] [Abstract][Full Text] [Related]
8. CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum.
Martínez-Pinilla E; Reyes-Resina I; Oñatibia-Astibia A; Zamarbide M; Ricobaraza A; Navarro G; Moreno E; Dopeso-Reyes IG; Sierra S; Rico AJ; Roda E; Lanciego JL; Franco R
Exp Neurol; 2014 Nov; 261():44-52. PubMed ID: 24967683
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization of GPCRs involved in endocrine regulation.
Kleinau G; Müller A; Biebermann H
J Mol Endocrinol; 2016 Jul; 57(1):R59-80. PubMed ID: 27151573
[TBL] [Abstract][Full Text] [Related]
10. Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer.
Ferré S; Lluis C; Lanciego JL; Franco R
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):596-600. PubMed ID: 20632968
[TBL] [Abstract][Full Text] [Related]
11. Heteromerization Modulates mu Opioid Receptor Functional Properties
Ugur M; Derouiche L; Massotte D
Front Pharmacol; 2018; 9():1240. PubMed ID: 30483121
[TBL] [Abstract][Full Text] [Related]
12. G Protein-Coupled Receptor Heteromers.
Gomes I; Ayoub MA; Fujita W; Jaeger WC; Pfleger KD; Devi LA
Annu Rev Pharmacol Toxicol; 2016; 56():403-25. PubMed ID: 26514203
[TBL] [Abstract][Full Text] [Related]
13. Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration.
Borroto-Escuela DO; Tarakanov AO; Guidolin D; Ciruela F; Agnati LF; Fuxe K
IUBMB Life; 2011 Jul; 63(7):463-72. PubMed ID: 21698749
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the Challenges of Detecting GPCR Oligomerization in the Brain.
Fernández-Dueñas V; Bonaventura J; Aso E; Luján R; Ferré S; Ciruela F
Curr Neuropharmacol; 2022; 20(6):1035-1045. PubMed ID: 34736381
[TBL] [Abstract][Full Text] [Related]
15. Targeting the receptor-based interactome of the dopamine D1 receptor: looking for heteromer-selective drugs.
Casadó-Anguera V; Cortés A; Casadó V; Moreno E
Expert Opin Drug Discov; 2019 Dec; 14(12):1297-1312. PubMed ID: 31507210
[No Abstract] [Full Text] [Related]
16. G-protein-coupled heteromers: regulation in disease.
Gomes I; Gupta A; Devi LA
Methods Enzymol; 2013; 521():219-38. PubMed ID: 23351742
[TBL] [Abstract][Full Text] [Related]
17. Heteromerization of dopaminergic receptors in the brain: Pharmacological implications.
Misganaw D
Pharmacol Res; 2021 Aug; 170():105600. PubMed ID: 33836279
[TBL] [Abstract][Full Text] [Related]
18. Impact of G protein-coupled receptor heteromers in endocrine systems.
Jonas KC; Hanyaloglu AC
Mol Cell Endocrinol; 2017 Jul; 449():21-27. PubMed ID: 28115188
[TBL] [Abstract][Full Text] [Related]
19. G-protein-coupled receptor type A heteromers as an emerging therapeutic target.
Guidolin D; Agnati LF; Marcoli M; Borroto-Escuela DO; Fuxe K
Expert Opin Ther Targets; 2015 Feb; 19(2):265-83. PubMed ID: 25381716
[TBL] [Abstract][Full Text] [Related]
20. Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.
Albizu L; Moreno JL; González-Maeso J; Sealfon SC
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):636-50. PubMed ID: 20632964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
